Therapy for multiple myeloma (MM) has markedly changed in the past decade with the introduction of new drugs, but it is not clear whether the improvements have been sustained. We studied 1038 patients diagnosed between 2001 and 2010, grouping patients into two 5-year periods by diagnosis, 2001-2005 and 2006-2010. The median estimated follow-up for the cohort was 5.9 years with 47% alive at the last follow-up. The median overall survival (OS) for the entire cohort was 5.2 years: 4.6 years for patients in the 2001-2005 group compared with 6.1 years for the 2006-2010 cohort (P ¼ 0.002). The improvement was primarily seen among patients over 65 years, the 6-year OS improving from 31 to 56%, Po0.001. Only 10% of patients died during the first year in the latter group, compared with 16% in the earlier cohort (Po0.01), suggesting improvement in early mortality. The improved outcomes were linked closely to the use of one or more new agents in initial therapy. The current results confirm continued survival improvement in MM and highlight the impact of initial therapy with novel agents. Most importantly, we demonstrate that the improved survival is benefitting older patients and that early mortality in this disease has reduced considerably.
INTRODUCTION
The treatment paradigms and outcomes for patients with multiple myeloma have markedly changed in the past decade with the introduction of several new, more effective and less toxic therapies and more than doubling of the survival. [1] [2] [3] Several studies toward the end of the last decade showed an improved survival compared with a nearly stagnant survival during the preceding three decades, where the treatment regimens primarily consisted of alkylating agents, anthracyclines and corticosteroids. 4, 5 During the past decade, we have continued to make a remarkable progress in our understanding of the disease biology as well as development of newer therapies, as a result of which we have been able to develop better risk-stratification models and risk-adapted treatment approaches. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] It is not clear whether the trend of improving survival seen in the earlier part of the last decade has continued as a result of these more recent advances. Furthermore, the previously described improvements in survival were primarily restricted to the younger patients, with the older patients having derived less benefit from the advances, likely a reflection of lower utilization of stem cell transplantation and reduced access to clinical trials evaluating new drugs. 5 As drugs are approved and become available outside clinical trials, and treating physicians become more comfortable with using these new drugs, older patients are more likely to receive such agents. Finally, it is not clear whether the prognostic factors identified in the era of older drugs are still of value in the current era with the new drugs with new methods of action. We designed the study with the specific goal of examining whether the survival improvement witnessed in myeloma is a sustained phenomenon, particularly in the older patients, and to evaluate the commonly recognized risk factors in the context of the newer therapies.
PATIENTS AND METHODS
The study included 1038 patients who were started on therapy for symptomatic multiple myeloma during a 10-year period, between 1 January 2001 and 31 December 2010, and seen at Mayo Clinic within 30 days of their diagnosis of symptomatic disease. Patients who had an organ involvement with light-chain amyloidosis at the time of diagnosis were excluded from the current analysis. Data regarding these patients were extracted from prospectively maintained databases and from review of medical records. Follow-up information on these patients is collected prospectively and entered at the time of each visit. For patients followed up at other institutions, annual follow-up letters are sent to patients to inquire about their disease status. All patients had consented to the use of their medical records, and the study was conducted in accordance with the institutional guidelines with approval of the institutional review board and in accordance with the principles of the Helsinki Declaration.
Fluorescent in situ hybridization (FISH) results were considered for analysis only if it was performed within 6 months of diagnosis or before the diagnosis of symptomatic myeloma. Tests with insufficient plasma cells for adequate analysis were not included in the analysis. FISH analysis was performed as previously described using the following probes: 3cen (D3Z1), 7cen (D7Z1), 9cen (D9Z1), 15cen (D15Z4), 11q13 (CCND1-XT), 14q32 (IGH-XT), 13q14 (RB1), 13q34 (LAMP1), 14q32 (5 0 IGH,3 0 IGH), 17p13.1 (p53) and 17cen (D17Z1). 19 The specificity of the detection process is improved using immune-fluorescent detection of the cytoplasmicimmunoglobulin (cIg-FISH) light chain in the plasma cells, as previously described. Patients were considered to have high-risk disease if FISH studies demonstrated one of the following abnormalities: t(4;14), t(14;16), t (14;20) or loss of p53 gene locus (del 17p or monosomy 17) in the absence of any trisomies. Patients with any of the other abnormalities or a normal FISH were considered to have standard risk multiple myeloma, as previously described. 7 The plasma cell labeling index (PCLI; a measure of the plasma-cell proliferation) was estimated using a slide-based immunofluorescence method on bone marrow samples, and expressed 1 as the percentage of immunoglobulin-positive cells that have taken up bromodeoxyuridine, as previously described. 20 Kaplan-Meier analysis was used for analyzing overall survival (OS), and the differences between the groups were tested for statistical significance using the two-tailed log-rank test. 21 Survival curves were generated with all patients surviving beyond 6 years censored at that time. Survival estimates and the confidence intervals (CIs) at different time points were estimated by using the Weibull method. Multivariate analysis of factors affecting survival was carried out using the Cox proportional hazards model. Optimal cut points for continuous variables affecting early death were identified by the examination of receiver operating characteristic analyses. Fisher's exact test was used to test differences in nominal variables. Differences in continuous variables between groups were compared using the Mann-Whitney or Kruskal-Wallis tests.
RESULTS
The patients were diagnosed between 2001 and 2010, with a median of 106 patients included from each year (range 77-128). The median age at diagnosis was 66 years (range 22-93) and 59% were male. Overall, 540 (52%) of the patients were over 65 years of age and 197 (19%) were over 75 years of age. The median estimated follow-up for the entire patient population was 5.9 years (95% CI 5.5, 6.3) and 53% had died at the time of the last follow-up. The baseline clinical characteristics are provided in Table 1 .
Survival outcomes
The median OS from diagnosis for the entire cohort was 5.2 years (95% CI 4.8, 5.8); the 6-year OS estimate was 45% (95% CI 42, 48). The median OS of the patients in the more recent group (n ¼ 561) was significantly longer compared with the earlier cohort (n ¼ 477): 6.1 years (95% CI 5.0, not reached (NR) and 4.6 years (95% CI 4.1, 5.2), respectively; P ¼ 0.002 (Figure 1a) . The 6-year OS estimates for the earlier cohort was significantly shorter compared with the recent cohorts and were 40% (95% CI 36, 44) and 51% (95% CI 46, 56), respectively, Po0.001. We also examined the trend along the years using 2-year intervals to examine the consistency in the improvements and as shown in Figure 1b ; there has been a consistent and steady improvement in survival over the time period studied. Given the limited improvement in survival seen among the older patients in the previous studies, 4, 5 we examined if the improved survival was limited to any age group. Notably, there was no survival improvement between the two time periods for patients p65 years. The median OS was NR for either time period among those p65 years ( Figure 1c ; P ¼ not significant). In contrast, among patients older than 65 years of age, the OS of the recent cohort was significantly longer, with a median of 5 years (95% CI 4.1, NR) compared with 3.2 years (95% CI 2.4, 3.8) for the earlier cohort ( Figure 1d ). We then specifically examined if within the group of patients over 65 years of age improved outcomes were noted in the very old (i.e. over 75 years of age) patients as well. Improved survival was seen among patients up to 75 years of age and those over 75 years of age as well (Supplementary Figures S1A and S1B).
Initial therapy and use of stem cell transplantation We then examined the impact of novel agents used as part of initial therapy on survival outcomes. The initial treatment regimen contained one or more of the novel drugs (thalidomide, lenalidomide or bortezomib) in 621 (60%) of the patients; a regimen incorporating two novel agents was used in 36 patients (3.5%). Lenalidomide dexamethasone was the most common induction regimen overall, with 345 (33%) patients receiving this regimen. The most common non-novel agent regimen used was single agent dexamethasone, with 249 patients receiving this regimen (24%) followed by melphalan and prednisone in 120 patients (12%). The distribution of the most commonly used initial regimens is shown in Table 2 . As expected, a significantly higher proportion of patients treated in the more recent group had received a novel agent as part of the initial therapy compared with the earlier group (89% vs 29%, Po0.001). The median OS for patients receiving at least one novel agent as part of the initial therapy was NR (95% CI 5.4, NR) compared with 3.8 years (95% CI 3.2, 4.5) for those not receiving a novel agent as part of initial therapy, Po0.001 ( Figure 2a) . We then performed a multivariable analysis including the diagnosis period and use of novel agents, and only the use of novel agents was associated with improved survival, suggesting that the improved survival in the recent years is mostly related to the increased use of novel agents as part of initial therapy. Among the entire cohort, 393 patients (37%) received an autologous stem cell transplant (SCT) at some point during the disease course, with a median time to transplantation of 5.9 months (range 2-95). Among patients p65 years of age 277/498 (56%) of patients have undergone an autologous SCT at the time of the last follow-up. We did a 6-month landmark analysis to examine the impact of an autologous SCT on OS. The median OS for patients receiving an SCT was NR compared with 4.9 years (95% CI 4.2, 5.3) for those not receiving an SCT, Po0.001 (Figure 2b) . On restricting the analysis to those p65 years of age, the OS was identical for those who had received an SCT compared with those who had not yet had a transplant, median NR for either group (Figure 2c ). Among the patients over 65 years of age, 116 (21%) underwent an SCT; the median OS for those undergoing an SCT was NR (95% CI 5.4, NR) compared with 3.1 years (95% CI 2.5, 3.7) for those who did not, Po0.01 (Figure 2d ).
Early mortality Overall, 136 (13%) of the patients died within 1 year of diagnosis, with the 1-year mortality being significantly lower for the recent group (10%) than for the older cohort (16%; P ¼ 0.004). The early mortality was significantly lower among the patients who had received one of the newer drugs as part of their initial therapy (8% vs 19%, Po0.001). We then examined the factors associated with early mortality, restricting our analysis to those patients who received a newer agent as part of their initial therapy, as that represents the current practice. Receiver operating characteristic curves were generated for the continuous variables to identify the optimal cut point, and the values were rounded for convenience and ease of use. We identified age 470 years, platelet count o200 Â 10 6 /dl, serum creatinine of 41.5 mg/dl, serum albumin o3.5 g/dl, serum beta 2 microglobulin 46.5 mg/dl and lactate dehydrogenase 4180 IU/dl as factors associated with early mortality. We first examined all the variables in a multivariable model, and identified age 470, serum albumin o3.5 g/dl and serum beta 2 microglobulin 46.5 mg/dl as factors independently predicting early mortality. Presence of none, one, two or three factors, respectively, was associated with a 3%, 5%, 9% or 53% risk of early mortality, Po0.001 (Figure 2e ).
Prognostic factors for survival
We then examined the value of previously identified prognostic factors, many of which were identified in the context of older Survival improvement in myeloma SK Kumar et al therapies, in this recent cohort of patients. Specifically, we examined how the prognostic factors may have changed across the two time periods. We first examined the prognostic value of the International Staging System among 916 patients in whom the data were available; the median OS was NR, 5.7 years and 2.1 years for stages 1, 2 and 3 in the earlier time period (Figure 3a ) compared with NR, NR and 4.2 years, respectively, during the second time period (Figure 3b ). FISH data from around diagnosis were available for only 50 (10%) patients from the first time period compared with 385 (69%) patients from the more recent time period. The median OS for patients with high-risk FISH (defined as presence of t(4;14), t(14;16), t(14;20) or del 17p in the absence of any trisomy) or standard-risk FISH was 2.3 years and NR, respectively, for the earlier time period (P ¼ 0.05; Figure 3c ) and 3.5 and NR, respectively, in the latter time period (Po0.001; Figure 3d ). We also examined the prognostic value of FISH-based risk status using the traditional definition of high-risk FISH, not taking into consideration the overlapping abnormality of trisomies (defined as presence of t(4;14), t(14;16), t (16;20) or del 17p).
The median OS for patients with high-risk FISH or standard-risk FISH was 2.4 years and NR, respectively, for the earlier time period (P ¼ 0.01; Supplementary Figure S2A ) and 5.1 and NR, respectively, in the latter time period (P ¼ 0.046; Supplementary Figure S2B) . Next, we examined the prognostic value of lactate dehydrogenase using a cutoff of 222 IU/dl (upper limit of normal for the laboratory). The median OS for patients with lactate dehydrogenase 4222 IU/dl and p222 IU/dl was 1.8 and 5.1 years, respectively, for the earlier time period (Supplementary Figure S2C ) and 3.0 and NR, respectively, in the latter time period, Po0.001 for both comparisons (Supplementary Figure S2D) . Given the important prognostic value of proliferation in myeloma that has been observed with different methods of assessing proliferation across different studies, we examined the prognostic value of the PCLI and how it has changed over time. Using the traditional cutoff of 1% for the PCLI, the median OS for patients with the PCLI X1% and o1% was 3.1 years and 5.3 years, respectively, for the earlier time period (Po0.001; Supplementary Figure S3A ) and 5.5 years and NR, respectively, in the latter time period; (P ¼ not significant; Supplementary Figure S3B) . However, using a higher cutoff of 3%, the median OS for patients with the PCLI X3% and o3% was 3.1 and 5.1 years, respectively, for the earlier time period (P ¼ 0.005; Supplementary Figure S3C ) and were 3.8 years and NR, respectively, in the latter time period (P ¼ 0.001; Supplementary Figure S3D ). The relative risks associated with the different prognostic factors during the two time periods are as shown in Table 3 .
DISCUSSION
The past few years have witnessed continuing advances in the understanding of myeloma biology, especially the ability to identify patients with high-risk disease based on a variety of techniques such as FISH analysis and gene-expression profiling techniques in addition to the traditionally recognized risk factors. 1, [6] [7] [8] [9] [10] 22 This improved understanding has been coupled with addition of new therapies, primarily new agents belonging to the immunomodulatory and proteasome inhibitor classes of drugs. [11] [12] [13] [14] [15] [16] [17] [18] These improvements have in turn led to better understanding of the differential impact of specific drugs in patients with specific high-risk features such as the use of bortezomib for patients with high-risk translocations and 17p deletion. 23, 24 The current analysis provides evidence supporting continued improvement in the survival outcomes within the past decade, with those patients identified in the second half enjoying longer survival, and confirms the continuation of the trend we started seeing in the early part of the last decade. What is striking, and very encouraging, is the significant improvement seen among the older patients, a group that was left behind in the early period of improved outcomes. This is likely a reflection of the increased use of the newer drugs among the older patients, as is suggested by the significantly higher proportion of patients in the second half receiving a regimen that contained one of the newer drugs. These results are in concordance with the phase 3 trials that demonstrated improved survival for patients over 65 years of age with the addition of thalidomide or bortezomib to melphalan and prednisone. [25] [26] [27] [28] [29] From the current analysis, the dominant driving factor behind the observed improvement appears to be the increased use of novel agents in the more recent period. However, the lack of a further improvement in survival among the younger patients highlights the need for continued innovation in the treatment approaches, in terms of introduction of novel drugs with different mechanisms of action compared with the 17, 18 A substantial proportion of patients eligible for SCT have received one in this current cohort. Although the survival of patients undergoing an SCT is better, as would be expected from the selection bias inherent in being eligible for an SCT, two aspects need to be highlighted. Among the group of patients p65 years of age, the OS was similar between those who had a transplant and those who still had not had one. This reflects our standard approach of collecting stem cells in all eligible patients and giving the patients the option of an early transplant or a delayed one at relapse, given the equivalent results with either approach. This result is consistent with our previous reports. 30 The improved survival among those over 65 years of age who had undergone an SCT reflects the improved outcomes among those with better performance status and lack of significant comorbidities, as they are likely to be considered for a transplant. It also highlights the feasibility and safety of this approach among selected older patients. 31, 32 Another aspect of the current results that is clearly encouraging is the significant decrease in the early mortality (death within 1 year of diagnosis) in myeloma. 33, 34 The population included in the current study gives a better real-world view of the changes in the early mortality, as we included only patients who were seen within 30 days of diagnosis. Even with this criteria, the actual proportion of patients dying early after diagnosis is likely to be higher, as many critically sick patients are unlikely to get to a tertiary referral center in a timely fashion. This has to be compared and contrasted with the early mortality figures that have been reported from the phase 3 trials performed during the last decade. Although confirming the trend that is observed here, the figures from the phase 3 trials are substantially lower, highlighting the skewed nature of patients who are eligible for enrollment in clinical trials. Using the current set of patients, we were able to identify specific factors that increased the risk of early mortality, which in turn can help us develop specific therapeutic approaches in the context of well-designed clinical trials for these high-risk patients. Similar findings were seen in a French study, albeit in a transplant-eligible patient population. 34 It is quite likely that the low albumin, elevated beta 2 microglobulin and age over 70 years reflect the presence of comorbidities that can result in a decreased ability to treat the disease in an effective manner compared with the rest of the patients and increase the risk of toxicities with the regimens currently used.
The changes in the treatment approaches and the specific mechanisms of the drugs utilized can clearly affect different aspects of biology in unique ways. Thus, we examined the various prognostic factors that have been described over time to see if they are still applicable in the era of newer therapies and improved OS. 7, 22, [35] [36] [37] Interestingly, nearly all the prognostic factors continue to identify patients with worse outcomes, with FISH-based high-risk stratification remaining a powerful tool for clinical use. One striking finding was the complete lack of prognostic value for the PCLI in the newer cohort using the traditional cutoff of 1%, a finding we had previously reported in the context of immunomodulatory-based therapies. 38, 39 However, using a higher cutoff of 3% still appears to identify patients with poor outcomes, and this is likely a reflection of the ability of the newer drugs to abrogate some of the mechanisms of poor prognosis associated with a high proliferative rate. It is possible that the inherent lack of sensitivity of this slide-based test may not allow adequate discrimination between those groups with high and low proliferation, and a different methodology with more sensitivity and or specificity may still have clinical utility. 20 To this end, the slide-based method is no longer being used at our institution and we have shifted to a flow-based method that determines the proportion of cells in the S-phase. This is particularly relevant, as proliferation signatures have been commonly identified as a poor prognostic factor in gene expression-based studies in myeloma. 40 In conclusion, the current results indicate continued improvement in the survival of patients with myeloma, reflecting the impact of improved therapies. It is particularly encouraging to note the improved outcomes in the elderly patients, and the decrease in early mortality, both of which likely reflect the use of new drugs that can be administered with less toxicity and achieve a more rapid control of the disease at the outset. Finally, identification of high-risk characteristics at diagnosis, especially, cytogenetic abnormalities, will allow us to direct our efforts toward the patients currently doing poorly, so that progress can continue to be made.
